End-of-day quote
Nasdaq
06:00:00 2024-05-14 pm EDT
|
5-day change
|
1st Jan Change
|
12.01
USD
|
-1.23%
|
|
-0.50%
|
+6.95%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
153.1
|
345.7
|
453.7
|
-
|
-
|
Enterprise Value (EV)
1 |
153.1
|
254
|
373.7
|
428.5
|
460.4
|
P/E ratio
|
-0.72
x
|
-3.18
x
|
-6.33
x
|
-5.81
x
|
-5.79
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
391
x
|
466
x
|
41.5
x
|
13.5
x
|
EV / Revenue
|
-
|
288
x
|
384
x
|
39.2
x
|
13.7
x
|
EV / EBITDA
|
-
|
-
|
-6.79
x
|
-11.4
x
|
60.6
x
|
EV / FCF
|
-
|
-
|
-7.77
x
|
-8.78
x
|
-5.02
x
|
FCF Yield
|
-
|
-
|
-12.9%
|
-11.4%
|
-19.9%
|
Price to Book
|
-
|
3.69
x
|
3.54
x
|
4.95
x
|
4.62
x
|
Nbr of stocks (in thousands)
|
16,399
|
36,598
|
41,740
|
-
|
-
|
Reference price
2 |
9.336
|
9.445
|
10.87
|
10.87
|
10.87
|
Announcement Date
|
3/28/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.883
|
0.9732
|
10.94
|
33.71
|
EBITDA
1 |
-
|
-
|
-55.06
|
-37.74
|
7.594
|
EBIT
1 |
-
|
-80.71
|
-71.05
|
-67.75
|
-47.99
|
Operating Margin
|
-
|
-9,140.88%
|
-7,300.62%
|
-619.24%
|
-142.39%
|
Earnings before Tax (EBT)
1 |
-
|
-88.7
|
-68.34
|
-75.02
|
-70.38
|
Net income
1 |
-38.7
|
-88.8
|
-66.72
|
-76.72
|
-81.17
|
Net margin
|
-
|
-10,056.85%
|
-6,856.2%
|
-701.19%
|
-240.84%
|
EPS
2 |
-12.94
|
-2.970
|
-1.718
|
-1.871
|
-1.876
|
Free Cash Flow
1 |
-
|
-
|
-48.1
|
-48.8
|
-91.7
|
FCF margin
|
-
|
-
|
-4,942.71%
|
-446.04%
|
-272.06%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.25
|
-
|
0.219
|
0.185
|
0.222
|
0.2692
|
0.2614
|
0.2207
|
EBITDA
|
-
|
-
|
-12.89
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.74
|
-
|
-12.96
|
-12.18
|
-15.33
|
-16.8
|
-18.52
|
-20.4
|
Operating Margin
|
-4,298%
|
-
|
-5,917.35%
|
-6,585.95%
|
-6,904.5%
|
-6,243.03%
|
-7,082.58%
|
-9,242.79%
|
Earnings before Tax (EBT)
1 |
-12.76
|
-
|
-17.53
|
-12.51
|
-16.06
|
-16.43
|
-17.33
|
-18.3
|
Net income
1 |
-12.88
|
-
|
-17.41
|
-12.5
|
-16.09
|
-16.01
|
-16.72
|
-18.01
|
Net margin
|
-5,150.8%
|
-
|
-7,951.14%
|
-6,756.22%
|
-7,249.1%
|
-5,949.2%
|
-6,395.32%
|
-8,162.43%
|
EPS
2 |
-0.3800
|
-2.530
|
-0.4800
|
-0.3400
|
-0.4400
|
-0.4190
|
-0.4350
|
-0.4590
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/29/23
|
8/29/23
|
11/15/23
|
3/18/24
|
5/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
6.69
|
Net Cash position
1 |
-
|
91.7
|
80
|
25.1
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
0.8805
x
|
Free Cash Flow
1 |
-
|
-
|
-48.1
|
-48.8
|
-91.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-80.6%
|
-
|
6.86%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
2.560
|
3.070
|
2.190
|
2.350
|
Cash Flow per Share
2 |
-
|
-
|
-1.990
|
-2.470
|
-
|
Capex
1 |
-
|
-
|
0.4
|
0.4
|
0.4
|
Capex / Sales
|
-
|
-
|
41.1%
|
3.66%
|
1.19%
|
Announcement Date
|
3/28/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
10.87
CHF Average target price
25.68
CHF Spread / Average Target +136.28% Consensus |
1st Jan change
|
Capi.
|
---|
| +6.95% | 500M | | +33.63% | 50.93B | | -0.09% | 42.12B | | +49.62% | 42.05B | | -4.96% | 29.18B | | +11.18% | 26.02B | | -21.95% | 18.9B | | +8.61% | 13.21B | | +24.73% | 12.17B | | +28.31% | 12.16B |
Other Biotechnology & Medical Research
|